Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK updated guidance on banned breast implant still goes against French position

This article was originally published in RAJ Devices

Executive Summary

The UK Medicines and Healthcare products Regulatory Agency has issued updated guidance related to the banned Poly Implant Prothèse (PIP) silicone breast implants, which remains in stark contrast with the recent recommendations of French regulatory authority Afssaps1.

You may also be interested in...



Coronavirus Update: Regeneron Gets Warp Speed Funding, Conflict Slowing Moderna's Progress

Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.

FDA Clears Medtronic’s LINQ II Remote Cardiac Monitor, Approves Abbott’s Bluetooth-Compatible ICDs

Medtronic will launch the LINQ II remotely programmable insertable cardiac monitor in the US and Europe this summer following FDA clearance. This week, the agency also approved Abbott's Gallant ICD and CRT-D devices, which communicate with Abbott's myMerlinPulse mobile app.

Opdivo Secures India Patent, Fends Off Multi-Party Opposition

India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel